Last reviewed · How we verify
FHND9041
FHND9041 is a small molecule drug that targets the molecular target.
FHND9041 is a small molecule drug that targets the molecular target. Used for Unknown.
At a glance
| Generic name | FHND9041 |
|---|---|
| Sponsor | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 3 |
Mechanism of action
FHND9041 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- FHND9041 Versus Afatinib for Non-small Cell Lung Cancer (PHASE3)
- First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |